(CercleFinance.com) – OSE Immunotherapeutics and the Center Hospitalier Universitaire de Nantes announce the end of patient recruitment in the FIRsT study, a phase 1/2 clinical trial.
This is the first study to evaluate immunotherapy FR104/VEL-101, a CD28 antagonist monoclonal antibody fragment, in patients who have received a kidney transplant.
This study is sponsored and conducted by the Center Hospitalier Universitaire de Nantes under a collaboration agreement with OSE Immunotherapeutics.
‘With our previous preclinical and now clinical evaluations of FR104, we hope to contribute to the development of an innovative and promising immunotherapy for patients who require long-term immunosuppressive treatment’, commented Professor Gilles Blancho, Director of the Institute of Urology-Nephrology Transplantation (ITUN) in Nantes.